International Stem Cell is preparing to file an FDA application to begin its stem cell therapy program for patients with Parkinson's disease. Company officials have met with the FDA to discuss preclinical testing. The treatment involves the use of progenitor cells that develop into neural cells and promote the production of dopamine.

Related Summaries